Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Inclusion criteria

• Documented infection with HIV-1 (ELISA- Western Blot)
• Outpatient of masculine or feminine gender
• In female patients any risk of pregnancy must be avoid: women at least 1 year past menopause or being confirmed sterile or having an effective contraceptive device
• No previous treatment with antiretroviral therapy
• CDC group C (except tuberculosis if CD4 count is over 350 /ml), CDC group B with CD4+ count under 350/ml and CDC group A with CD4 count under 200/ml.
• Patient has provided informed written consent
• Patient must agree not to take any concomitant medication throughout the duration of the study without first informing the investigator

Exclusion criteria

• Deficiency of the patient rendering participation in the study or understanding of the information imparted difficult or even impossible
• Patient participating in a different clinical study
• Presence of serious or developing pathology
• Severe liver failure (TP under 50% et bilirubinemia over 3 LSN)
• Thrombocytopenia with platelet level under 50 000 cells /ml
• Known severe renal pathology (creatinine clearance under 50 ml/min)
• Clinical or biological problem corresponding to indications of grade over or equal 3 of WHO classification
• Karnofsky under 70 percent
• Opportunistic infections
• Patients taking medications not recommended in the context of the protocol